References

1. McInnes IB, Schett G (2011) The pathogenesis of rheumatoid arthritis. N Engl J Med 365: 2205-2219. View
2. Sainz de la Maza M, Molina N, Gonzalez-Gonzalez LA, Doctor PP, Tauber J, et al. (2012) Clinical characteristics of a large cohort of patients with scleritis and episcleritis. Ophthalmology 119: 43-50. View
3. Zlatanović G, Veselinović D, Cekić S, Živković M, Đorđević-Jocić J, et al. (2010) Ocular manifestation of rheumatoid arthritis-different forms and frequency. Bosn J Basic Med Sci 10: 323. View
4. Turesson C, O’fallon W, Crowson C, Gabriel S, Matteson EL, et al. (2003) Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. Ann Rheum Dis 62: 722-727. View
5. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 5: 75-92. View
6. Nelson JD, Craig JP, Akpek EK, Azar DT, Belmonte C, et al. (2017) TFOS DEWS II Introduction. Ocul Surf 15: 269-275. View
7. Cimmino MA, Salvarani C, Macchioni P, Montecucco C, Fossaluzza V, et al. (2000) Extra-articular manifestations in 587 Italian patients with rheumatoid arthritis. Rheumatol Int 19: 213-217. View
8. Lemp MA (2005) Dry eye (keratoconjunctivitis sicca), rheumatoid arthritis, and Sjögren’s syndrome. Am J Ophthalmol 140: 898-899. View
9. Wi Y, Asbell P. The Core Mechanism of Dry Eye Disease Is Inflammation. Eye Contact Lens 40: 311-311. View
10. Uchino Y, Kawakita T, Miyazawa M, Ishii T, Onouchi H, et al. (2012) Oxidative stress induced inflammation initiates functional decline of tear production. PLoS One 7: e45805. View
11. Higuchi A, Inoue H, Kawakita T, Ogishima T, Tsubota K, et al. (2012) Selenium compound protects corneal epithelium against oxidative stress. PLoS One 7: e45612. View
12. Pflugfelder SC, Jones D, Ji Z, Afonso A, Monroy D, et al. (1999) Altered cytokine balance in the tear fluid and conjunctiva of patients with Sjögren's syndrome keratoconjunctivitis sicca. Curr Eye Res 19: 201-211. View
13. Enriquez-de-Salamanca A, Castellanos E, Stern ME, Fernández I, Carreño E et al. (2010) Tear cytokine and chemokine analysis and clinical correlations in evaporative-type dry eye disease. Mol Vis 16: 862-873. View
14. Bron AJ, de Paiva CS, Chauhan SK, Bonini S, Gabison EE, et al. (2017) TFOS DEWS II pathophysiology report. Ocul Surf 15: 438-510. View
15. Sonawane S, Khanolkar V, Namavari A, Chaudhary S, Gandhi S, et al. (2012) Ocular surface extracellular DNA and nuclease activity imbalance: a new paradigm for inflammation in dry eye disease. Invest Ophthalmol Vis Sci 53: 8253-8263. View
16. Bian F, Pelegrino FS, Henriksson JT, Pflugfelder SC, Volpe EA, et al. (2016) Differential Effects of Dexamethasone and Doxycycline on Inflammation and MMP Production in Murine Alkali-Burned Corneas Associated with Dry Eye. Ocul Surf 14: 242-254. View
17. Chen Y, Chauhan SK, Saban DR, Sadrai Z, Okanobo A, et al. (2011) Interferongamma- secreting NK cells promote induction of dry eye disease. J Leukoc Biol 89: 965-972. View
18. You IC, Coursey TG, Bian F, Barbosa FL, de Paiva CS, et al. (2015) Macrophage Phenotype in the Ocular Surface of Experimental Murine Dry Eye Disease. Arch Immunol Ther Exp (Warsz) 63: 299-304. View
19. Stern ME, Gao J, Schwalb TA, Ngo M, Tieu DD, et al. Conjunctival T-cell subpopulations in Sjogren's and non-Sjogren's patients with dry eye. Invest Ophthalmol Vis Sci 43: 2609-2614. View
20. Chi W, Zhu X, Yang P, Liu X, Lin X, et al. (2008) Upregulated IL-23 and IL-17 in Behcet patients with active uveitis. Invest Ophthalmol Vis Sci 49: 3058- 3064. View
21. De Paiva CS, Chotikavanich S, Pangelinan SB, Pitcher JD 3rd, Fang B, et al. IL- 17 disrupts corneal barrier following desiccating stress. Mucosal Immunol 2: 243-253. View
22. Komiyama Y, Nakae S, Matsuki T, Nambu A, Ishigame H, et al. (2006) IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol 177: 566-573. View
23. Nakae S, Nambu A, Sudo K, Iwakura Y (2003) Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 171: 6173-6177. View
24. Messmer EM (2015) The pathophysiology, diagnosis, and treatment of dry eye disease. Dtsch Arztebl Int 112: 71-81. View
25. Lin H, Yiu SC (2014) Dry eye disease: a review of diagnostic approaches and treatments. Saudi J Ophthalmol 28: 173-181. View
26. McGinnigle S, Naroo SA, Eperjesi F (2012) Evaluation of dry eye. Surv Ophthalmol 57: 293-316. View
27. Nelson JD (1995) Simultaneous evaluation of tear turnover and corneal epithelial permeability by fluorophotometry in normal subjects and patients with keratoconjunctivitis sicca (KCS). Trans Am Ophthalmol Soc 93: 709. View
28. Karampatakis V, Karamitsos A, Skriapa A, Pastiadis G (2010) Comparison between normal values of 2- and 5-minute Schirmer test without anesthesia. Cornea 29: 497-501. View
29. Lucca JA, Nunez JN, Farris RL (1990) A comparison of diagnostic tests for keratoconjunctivitis sicca: lactoplate, Schirmer, and tear osmolarity. CLAO 16: 109-112. View
30. Artifoni M, Rothschild PR, Brézin A, Guillevin L, Puéchal X, et al. (2014) Ocular inflammatory diseases associated with rheumatoid arthritis. Nat Rev Rheumatol 10: 108. View
31. Craig JP, Nelson JD, Azar DT, Belmonte C, Bron AJ, et al. (2017) TFOS DEWS II Report Executive Summary. Ocul Surf 15: 802-812. View
32. Ames P, Galor A (2015) Cyclosporine ophthalmic emulsions for the treatment of dry eye: a review of the clinical evidence. Clin Investig (Lond) 5: 267. View
33. Restasis New FDA Drug Approval / Center Watch.
34. Xiidra New FDA Drug Approval / Center Watch.
35. Sun Pharma announces US FDA Approval of Cequa to Treat Dry Eye DIsease. Sun Pharmaceutical Industries Ltd.
36. Sheppard JD, Donnenfeld ED, Holland EJ, Slonim CB, Solomon R, et al. (2014) Effect of loteprednol etabonate 0.5% on initiation of dry eye treatment with topical cyclosporine 0.05%. Eye Contact Lens 40: 289-296. View
37. Pflugfelder SC, Solomon A, Stern ME (2000) The diagnosis and management of dry eye: a twenty-five–year review. Cornea 19: 644-649. View
38. ClinicalTrials.gov. Ocular tolerability of voclosporin ophthalmic solution versus Restasis® in subjects with dry eye disease.
39. ClinicalTrials.gov. Evaluation of Systane complete for the treatment of contact lens discomfort.
40. ClinicalTrials.gov. Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05% Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes.
41. ClinicalTrials.gov. Cross-linked Hyaluronic Acid and Coenzyme Q10 in the Treatment of Dry Eye (DEDCO).
42. Dry Eye Assessment and Management Study Research Group, Asbell PA, Maguire MG, Pistilli M, Ying GS, et al. n-3 Fatty Acid Supplementation for the Treatment of Dry Eye Disease. N Engl J Med 378: 1681-1690. View
43. Roncone M, Bartlett H, Eperjesi F (2010) Essential fatty acids for dry eye: A review. Contact Lens and Anterior Eye 33: 49-54. View
44. ClinicalTrials.gov. A Multi-Center, Randomized, Double Masked, Parallel- Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease.
45. ClinicalTrials.gov. Intense Pulse Light Treatment With Meibomian Gland Expression of the Upper Eyelids in Dry Eye Disease.
46. EJea H (2017) "Intranasal tear neurostimulation for subjects with dry eye disease: results from 2 pivotal clinical trials" AAO. American Academy of Ophthalmology.
47. Yavuz S, Asfuroğlu E, Bicakcigil M, Toker E (2011) Hydroxychloroquine improves dry eye symptoms of patients with primary Sjogren’s syndrome. Rheumatol Int 31: 1045-1049. View
48. Cojocaru M, Cojocaru IM, Silosi I, Vrabie CD, Tanasescu R, et al. (2010) Extraarticular manifestations in rheumatoid arthritis. Maedica 5: 286-291. View
49. Watson PG, Young RD (2004) Scleral structure, organisation and disease. Exp Eye Res 78: 609-623. View
50. Salama A, Elsheikh A, Alweis R (2018) Is this a worrisome red eye? Episcleritis in the primary care setting. J Community Hosp Intern Med Perspect 8: 46- 48. View
51. Hannum CH, Wilcox CJ, Arend WP, Joslin FG, Dripps DJ, et al. (1990) Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 343: 336-340. View
52. Gupta A, Monroy D, Ji Z, Yoshino K, Huang A, et al. (1996) Transforming growth factor beta-1 and beta-2 in human tear fluid. Curr Eye Res 15: 605- 614. View
53. Villani E, Galimberti D, Papa ND, Nucci P, Ratiglia R, et al. (2013) Inflammation in dry eye associated with rheumatoid arthritis: cytokine and in vivo confocal microscopy study. Innate Immun 19: 420-427. View
54. Akpek EK, Uy HS, Christen W, Gurdal C, Foster CS, et al. (1999) Severity of episcleritis and systemic disease association. Ophthalmology 106: 729-731. View
55. Williams C, Browning A, Sleep T, Webber S, McGill J, et al. (2005) A randomised, double-blind trial of topical ketorolac vs artificial tears for the treatment of episcleritis. Eye 19: 739-742. View
56. Leibowitz H, Hyndiuk R, Lindsey C, Rosenthal A (1984) Fluorometholone acetate: clinical evaluation in the treatment of external ocular inflammation. Ann Ophthalmol 16: 1110-1115. View
57. de la Maza MS, Molina N, Gonzalez-Gonzalez LA, Doctor PP, Tauber J, et al. (2012) Clinical characteristics of a large cohort of patients with scleritis and episcleritis. Ophthalmology 119: 43-50. View
58. Watson P, Hayreh S (1976) Scleritis and episcleritis. Br J Ophthalmol 60: 163-191. View
59. Wakefield D, Di Girolamo N, Thurau S, Wildner G, McCluskey P, et al. (2013) Scleritis: challenges in immunopathogenesis and treatment. Discov Med 16: 153-157. View
60. Wu CC, Yen JH, Tsai WC, Liu HW, Yu HC, et al. (2005) Rare Extra-articular Manifestation of Rheumatoid Arthritis: Scleromalacia Perforans. Kaohsiung J Med Sci 21: 233-235. View
61. Sims J (2012) Scleritis: presentations, disease associations and management. Postgrad Med J 88: 713-718. View
62. Wakefield D, Di Girolamo N, Thurau S, Wildner G, McCluskey P, et al. (2013) Scleritis: challenges in immunopathogenesis and treatment. Discov Med 16: 153-157. View
63. Benson WE, Shields JA, Tasman W, Crandall AS (1979) Posterior scleritis a cause of diagnostic confusion. Arch Ophthalmol 97: 1482-1486. View
64. Bernauer W, Watson PG, Daicker B, Lightman S (1994) Cells perpetuating the inflammatory response in scleritis. Br J Ophthalmol 78: 381-385. View
65. Haworth C, Brennan FM, Chantry D, Turner M, Maini RN, et al. (1991) Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-α. Eur J Immunol 21: 2575-2579. View
66. Brennan F, Jackson A, Chantry D, Maini R, Feldmann M, et al. (1989) Inhibitory effect of TNFα antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 334: 244-247. View
67. Rao NA, Marak GE, Hidayat AA (1985) Necrotizing Scleritis: A Clinicopathologic Study of 4l Cases. Ophthalmology 92: 1542-1549. View
68. Rao NA, Marak GE, Hidayat AA (1985) Necrotizing scleritis. A clinicopathologic study of 41 cases. Ophthalmology 92: 1542-1549. View
69. Usui Y, Parikh J, Goto H, Rao NA (2008) Immunopathology of necrotising scleritis. Br J Ophthalmol 92: 417-419. View
70. Hoang LT, Lim LL, Vaillant B, Choi D, Rosenbaum JT, et al. (2008) Antineutrophil Cytoplasmic Antibody-Associated Active Scleritis. Arch Ophthalmol 126: 651-655. View
71. Amadi-Obi A, Yu CR, Liu X, Mahdi RM, Clarke GL, et al. (2007) TH 17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med 13: 711-718. View
72. Girolamo ND, Verma MJ, McCluskey PJ, Lloyd A, Wakefield D, et al. (1996) Increased matrix metalloproteinases in the aqueous humor of patients and experimental animals with uveitis. Curr Eye Res 15: 1060-1068. View
73. Quist TS, Vogelgesang S, Goins KM (2018) Scleritis: A Case Report and Overview. Eye Roundsorg University of Iowa.
74. Rudd JC (1998) Posterior Scleritis. Digital Journal of Ophthalmology.
75. Bauer AM, Fiehn C, Becker MD (2005) Celecoxib, a selective inhibitor of cyclooxygenase 2 for therapy of diffuse anterior scleritis. Am J Ophthalmol 139: 1086-1089. View
76. Agrawal R, Lee CS, Gonzalez-Lopez JJ, Khan S, Rodrigues V, et al. (2016) Flurbiprofen: a nonselective cyclooxygenase (COX) inhibitor for treatment of noninfectious, non-necrotizing anterior scleritis. Ocul Immunol Inflamm 24: 35-42. View
77. Jabs DA, Rosenbaum JT, Foster CS, Holland GN, Jaffe GJ, et al. (2000) Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 130: 492-513. View
78. Murphy CC, Ayliffe WH, Booth A, Makanjuola D, Andrews PA, et al. (2004) Tumor necrosis factor α blockade with infliximab for refractory uveitis and scleritis. Ophthalmology 111: 352-356. View
79. Sohn EH, Wang R, Read R, et al. Long-term, multicenter evaluation of subconjunctival injection of triamcinolone for non-necrotizing, noninfectious anterior scleritis. Ophthalmology 118: 1932-1937. View
80. Bhatt N, Dalal M, Tucker W, Obiyor D, Nussenblatt R, et al. (2015) Subconjunctival sirolimus in the treatment of autoimmune non-necrotizing anterior scleritis: results of a phase I/II clinical trial. Am J Ophthalmol 159: 601-606. View
81. Knickelbein JE, Tucker WR, Bhatt N, Armbrust K, Valent D, et al. (2016) Gevokizumab in the Treatment of Autoimmune Non-necrotizing Anterior Scleritis: Results of a Phase I/II Clinical Trial. Am J Ophthalmol 172: 104-110. View
82. Doctor P, Sultan A, Syed S, Christen W, Bhat P, et al. (2010) Infliximab for the treatment of refractory scleritis. Br J Ophthalmol 94: 579-583. View
83. ClinicalTrials.gov. Cyclophosphamide vs. Infliximab for Refractory Idiopathic Scleritis (CIRIS) (CIRIS).
84. O'Neil EC, Huang J, Suhler EB, Dunn JP Jr, Perez VL, et al. (2018) Iontophoretic delivery of dexamethasone phosphate for non-infectious, non-necrotising anterior scleritis, dose-finding clinical trial. Br J Ophthalmol 102: 1011-1013. View
85. Suhler EB, Lim LL, Beardsley RM, Giles TR, Pasadhika S, et al. (2014) Rituximab therapy for refractory scleritis: results of a phase I/II doseranging, randomized, clinical trial. Ophthalmology 121: 1885-1891. View
86. ClinicalTrials.gov. Tofacitinib for Inflammatory Eye Disease.
87. McKibbin M, Isaacs J, Morrell A (1999) Incidence of corneal melting in association with systemic disease in the Yorkshire Region, 1995-7. Br J Ophthalmol 83: 941-943. View
88. Galor A, Thorne JE (2007) Scleritis and peripheral ulcerative keratitis. R Rheum Dis Clin North Am 33: 835-854. View
89. Sharma N, Sinha G, Shekhar H, Titiyal JS, Agarwal T, et al. (2015) Demographic profile, clinical features and outcome of peripheral ulcerative keratitis: a prospective study. Br J Ophthalmol 99: 1503-1508. View
90. Freeman RD (1972) Oxygen consumption by the component layers of the cornea. J Physiol 225: 15-32. View
91. Yagci A (2012) Update on peripheral ulcerative keratitis. Clin Ophthalmol 6:747-754. View
92. Huerva V, Ascaso FJ, Grzybowski A (2014) Infliximab for peripheral ulcerative keratitis treatment. Medicine 93: 176. View
93. Cao Y, Zhang W, Wu J, Zhang H, Zhou H, et al. (2017) Peripheral ulcerative keratitis associated with autoimmune disease: pathogenesis and treatment. J Ophthalmol. View
94. Smith V, Hoh H, Easty D (1999) Role of ocular matrix metalloproteinases in peripheral ulcerative keratitis. Br J Ophthalmol 83: 1376-1383. View
95. Dana MR, Qian Y, Hamrah P (2000) Twenty-five–Year Panorama of Corneal Immunology: Emerging Concepts in the Immunopathogenesis of Microbial Keratitis, Peripheral Ulcerative Keratitis, and Corneal Transplant Rejection. Cornea 19: 625-643. View
96. Tauber J, de la Maza MS, Hoang-Xuan T, Foster CS (1990) An Analysis of Therapeutic Decision Making Regarding Immunosuppressive Chemotherapy. Cornea 9: 66-73. View
97. Kraus CL, Culican SM (2012) Use of biologic agents in ocular manifestations of rheumatic disease. Int J Rheumatol 2012: 203819. View
98. Messmer EM, Foster CS (1999) Vasculitic peripheral ulcerative keratitis. Surv Ophthalmol 43: 379-396. View
99. Caimmi C, Crowson CS, Smith WM, Matteson EL, Makol A, et al. (2018) Clinical correlates, outcomes, and predictors of inflammatory ocular disease associated with rheumatoid arthritis in the biologic era. The Journal of rheumatology 45: 595-603. View
100. Levitt AE, McManus KT, McClellan AL, Davis J, Goldhardt R, et al. (2015) Ocular inflammation in the setting of concomitant systemic autoimmune conditions in an older male population. Cornea 34: 762-767. View
101. Lee SY, Chung WT, Jung WJ, Lee SW (2012) Retrospective study on the effects of immunosuppressive therapy in uveitis associated with rheumatic diseases in Korea. Rheumatol Int 32: 3903-3908. View
102. Becker M, Adamus G, Davey M, Rosenbaum J (2000) The role of T cells in autoimmune uveitis. Ocul Immunol Inflamm 8: 93-100. View
103. Escobar T, Yu CR, Muljo SA, Egwuagu CE (2013) STAT3 activates miR-155 in Th17 cells and acts in concert to promote experimental autoimmune uveitis. Invest Ophthalmol Vis Sci 54: 4017-4025. View
104. Samuels JS, Holland L, López M, Meyers K, Cumbie WG, et al. Prostaglandin E2 and IL-23 interconnects STAT3 and RoRγ pathways to initiate Th17 CD4+ T-cell development during rheumatoid arthritis. Inflamm Res 67: 589-596. View
105. Silveira I, Burlingame R, von Mühlen C, Bender A, Staub H, et al. (2007) Anti- CCP antibodies have more diagnostic impact than rheumatoid factor (RF) in a population tested for RF. Clin Rheumatol 26: 1883-1889. View
106. Wladis EJ, Pappa C, Cavaliere LF (2011) Anticyclic-citrullinated protein antibodies in the diagnosis of ophthalmic inflammatory disease. Ophthalmic Plast Reconstr Surg 27: e1-e2. View
107. Karti O, Ayhan Z, Zengin MO, Kaya M, Kusbeci T, et al. (2018) Choroidal Thickness Changes in Rheumatoid Arthritis and the Effects of Short-term Hydroxychloroquine Treatment. Ocul Immunol Inflamm 26: 770-775. View
108. Calvo-Río V, de la Hera D, Beltrán-Catalán E, Blanco R, Hernandez M, et al. Tocilizumab in uveitis refractory to other biologic drugs: a study of 3 cases and a literature review. Clin Exp Rheumatol 32: S54-S57. View
109. Mesquida M, Molins B, Llorenç V, de la Maza MS, Adan A, et al. (2017) Targeting interleukin-6 in autoimmune uveitis. Autoimmun Rev 16: 1079- 1089. View
110. Jaffe GJ, Dick AD, Brezin AP, Nguyen QD, Thorne JE, et al. (2016) Adalimumab in Patients with Active Noninfectious Uveitis. N Engl J Med 375: 932-943. View
111. Nguyen QD, Merrill PT, Jaffe GJ, Dick AD, Kurup SK, et al. (2016) Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet 388: 1183-1192. View
112. van Bentum RE, Heslinga SC, Nurmohamed MT, Gerards AH, Griep EN, et al. (2019) Reduced Occurrence Rate of Acute Anterior Uveitis in Ankylosing Spondylitis Treated with Golimumab - The GO-EASY Study. J Rheumatol 46: 153-159. View
113. Aldeyra Therapeutics Phase 3 SOLACE Trial Fails to Meet Primary Endpoint in Noninfectious Anterior Uveitis.
114. Ramanan AV, Dick AD, Jones AP, Guly C, Hardwick B, et al. (2018) A phase II trial protocol of Tocilizumab in anti-TNF refractory patients with JIAassociated uveitis (the APTITUDE trial). BMC Rheumatology 2: 4. View
115. EULAR, Ramanan AV (2019) Ann Rheum Dis (suppl 2): 265. View